Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · IEX Real-Time Price · USD
22.15
-0.32 (-1.42%)
At close: Jul 2, 2024, 4:00 PM
21.70
-0.45 (-2.03%)
After-hours: Jul 2, 2024, 7:35 PM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 526 employees as of December 31, 2023. The number of employees decreased by 72 or -12.04% compared to the previous year.
Employees
526
Change (1Y)
-72
Growth (1Y)
-12.04%
Revenue / Employee
$100,008
Profits / Employee
-$923,008
Market Cap
2.14B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 526 | -72 | -12.04% |
Dec 31, 2022 | 598 | 113 | 23.30% |
Dec 31, 2021 | 485 | 173 | 55.45% |
Dec 31, 2020 | 312 | 42 | 15.56% |
Dec 31, 2019 | 270 | 59 | 27.96% |
Dec 31, 2018 | 211 | 16 | 8.21% |
Dec 31, 2017 | 195 | 91 | 87.50% |
Dec 31, 2016 | 104 | 43 | 70.49% |
Dec 31, 2015 | 61 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fortrea Holdings | 19,000 |
Patterson Companies | 7,600 |
QuidelOrtho | 7,100 |
Evolent Health | 4,700 |
CONMED | 4,000 |
Myriad Genetics | 2,700 |
Indivior | 1,164 |
Privia Health Group | 1,102 |
NTLA News
- 12 hours ago - Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm - PRNewsWire
- 6 days ago - Intellia Therapeutics Announces CFO Transition - GlobeNewsWire
- 7 days ago - Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform - GlobeNewsWire
- 8 days ago - 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More - Benzinga
- 15 days ago - Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024 - GlobeNewsWire
- 18 days ago - Intellia Therapeutics Names Brian Goff to its Board of Directors - GlobeNewsWire
- 4 weeks ago - Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) - GlobeNewsWire
- 7 weeks ago - Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire